within Pharmacolibrary.Drugs.ATC.L;

model L03AB03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.004616666666666667,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00011999999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00035999999999999997,
    k12             = 9.4,
    k21             = 9.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AB03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Interferon gamma (IFN-γ) is a cytokine produced by lymphocytes, especially T-lymphocytes and natural killer cells, and is involved in innate and adaptive immunity. Recombinant human interferon gamma is used as an immunomodulatory agent in the treatment of chronic granulomatous disease and severe malignant osteopetrosis. It is approved for use in certain immune deficiencies and is not typically used in standard antiviral therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single intravenous dose of recombinant human interferon gamma.</p><h4>References</h4><ol><li><p>Kelly, CP, et al., &amp; Miller, SD (2021). TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Gastroenterology</i> 161(1) 66–80.e8. DOI:<a href=&quot;https://doi.org/10.1053/j.gastro.2021.03.014&quot;>10.1053/j.gastro.2021.03.014</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33722583/&quot;>https://pubmed.ncbi.nlm.nih.gov/33722583</a></p></li><li><p>Sedic, M, et al., &amp; Smith, PF (2018). Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey. <i>Veterinary pathology</i> 55(2) 341–354. DOI:<a href=&quot;https://doi.org/10.1177/0300985817738095&quot;>10.1177/0300985817738095</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29191134/&quot;>https://pubmed.ncbi.nlm.nih.gov/29191134</a></p></li><li><p>Seckinger, A, et al., &amp; Vu, MD (2017). Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. <i>Cancer cell</i> 31(3) 396–410. DOI:<a href=&quot;https://doi.org/10.1016/j.ccell.2017.02.002&quot;>10.1016/j.ccell.2017.02.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28262554/&quot;>https://pubmed.ncbi.nlm.nih.gov/28262554</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AB03;
